Bioanalytical Systems, Inc (NASDAQ:BASI) reported on Friday that Chief Financial Officer Jacqueline M. Lemke has been appointed to the additional posts of interim President and Chief Executive Officer. Ms. Lemke succeeds Anthony S. Chilton, who has quitted as Chief Executive Officer to pursue other options.
Chairman John B. Landis stated that Jacqueline Lemke has demonstrated exceptional skill, energy and commitment since she joined BASI as Chief Financial Officer 3 months ago. Landis further stated that in this short period she has considerably lowered the corporation’s cost structure, refocused their marketing program, and instituted aggressive performance objectives for all operating departments.
Lemke has over 20 years of experience in critical financial reporting and management positions, recently as Vice President of Finance and Global CFO of Remy, Inc.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Charles River Laboratories (NYSE:CRL) fell -3.15% to settle at $33.21, PAREXEL International Corporation (NASDAQ:PRXL) moved down -1.14% to end at $28.50 while Covance Inc. (NYSE:CVD) plunged -1.18% to finish on Friday at $47.07.
Bioanalytical Systems, Inc. (NASDAQ:BASI) on July 06, 2012 increased +2.26% to the closing price of $0.90. The overall volume in the last trading session was 3,480.00 shares. Its fifty two week range was $0.81-$2.15. The total market capitalization remained $6.55 million.
BASI is ahead its 52 week low with +11.10% and going forward from its 52 week high price with -58.14%. BASI last month stock price volatility remained 4.18%. In its share capital BASI has 7.28 million outstanding shares among them 5.98 million shares have been floated in market exchange. BASI stock institutional ownership remained 3.56% while insider ownership included 0.01%.
The stock price of BASI is moving down from its 20 days moving average with -0.12% and remote negatively from 50 days moving average with -15.57%. BASI current year earnings per share experienced a downfall of -20.05% while its current quarter performance remained -34.79%. Company’s beta coefficient included 1.71. Beta factors measures the amount of market risk associated with market trade.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL